Neimeth International Pharmaceuticals Plc posted a pre-tax profit of N1.49 billion for the year ended December 31, 2025, marking a strong turnaround from the pre-tax loss of N854.43 million recorded in 2024.
The company’s financial results filed to the Nigerian Exchange (NGX) showed that the impressive performance was bolstered by a N48 million foreign exchange gain, compared to a loss of over N2 billion in the prior year.
This represents a significant improvement of 274% year-on-year.
For Q4 2025 alone, the company delivered a profit before tax of N1.15 billion, compared to a loss of N1.16 billion in Q4 2024 and a pre-tax profit of N340 million in Q3 2025, underscoring a sharp recovery in performance.
Key highlights
- Revenue: N7.37 billion (Up 64% YoY from N4.49 billion)
- Gross Profit: N3.35 billion (Up 71% YoY from N1.96 billion)
- Operating Profit: N2.71 billion (from N18.89 million in 2024)
- Profit Before Tax: N1.49 billion (from a loss of N854.43 million in 2024)
- Profit After Tax: N982.11 million (from a loss of N885.33 million in 2024)
- Basic & Diluted Earnings Per Share: 22.98 Kobo (Up from -20.72 Kobo)
- Total Assets: N14.93 billion (Up from N11.99 billion)
- Cash & Cash Equivalents: N1.61 billion (Down from N2.15 billion)
- Total External Debt: N9.68 billion (Up from N5.36 billion)
